查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403496

到 2030 年感觉异常治疗市场预测：按类型、治疗方法、原因、分销管道、最终用户和地区进行的全球分析

Paresthesia Treatment Market Forecasts to 2030 - Global Analysis By Type, Treatment, Cause, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球感觉异常治疗市场规模为 53.9 亿美元，预计在预测期内复合年增长率为 5.6%，到 ​​2030 年将达到 78.9 亿美元。

感觉异常治疗市场是一个经济领域，涵盖各种旨在诊断、管理和缓解感觉异常症状（一种以麻木、麻木和灼热感等异常感觉为特征的神经系统疾病）的产品和服务。我们提供多种治疗方案，包括药物、神经调节剂和復健疗法，以缓解麻木症状及其根本原因。

根据世界卫生组织(WHO)预测，2020年60岁以上人口预计将达到约10亿，2030年将超过14亿。

慢性病增加

随着糖尿病、神经病变和自体免疫疾病等慢性疾病的日益流行，以刺痛和麻木等异常感觉为特征的感觉异常的发生率也相应增加。感觉异常通常是潜在医疗问题的症状，增加了对有效治疗方法和管理策略的需求。此外，医疗保健提供者被迫应对越来越多寻求缓解与感觉障碍相关的不适的患者，从而推动了治疗市场的扩张。

某些治疗方法可能产生的副作用

神经刺激和药物治疗等干预措施可能会导致某些患者出现不良反应、不适和併发症。因此，对安全性和耐受性的担忧可能会限制患者和医生的接受度，并可能阻止这些治疗方法的广泛使用。然而，个体对治疗的反应各不相同，医疗保健提供者面临着仔细评估和为每位患者量身定制干预措施的挑战。

对神经调节治疗的需求不断增长

神经调节包括脊髓刺激和周边神经刺激等多种程序，已成为治疗感觉麻痹和相关神经病变的有效方法。随着神经病变和脊椎疾病等慢性疾病的盛行率不断增加，治疗性介入的需求不断增长。神经调节技术提供客製化的微创解决方案，当传统治疗方法被认为不足时，为患者提供可行的替代方案。

与目前治疗方法相关的负面结果

目前治疗方法可能产生的副作用和併发症对麻醉治疗市场构成严重威胁。麻木的治疗方法可能会带来感染、设备故障和无意的神经损伤等风险，包括脊髓刺激和药物治疗。然而，替代疗法和新兴市场技术的开拓可能会威胁现有治疗方法的市场力量。为了在不断变化的感觉障碍治疗市场中减轻这些风险，保持当前策略的安全性和有效性并继续创新至关重要。

COVID-19 的影响：

感觉异常治疗市场受到了 COVID-19 大流行的严重影响。由于医疗保健服务中断、供应链问题以及重点转向流行病管理，麻醉药物的创造和普及已经放缓。然而，对远端医疗和远端患者监护的日益重视为线上咨询和家庭治疗提供了机会。随着医疗保健行业在技术发展和常规护理回归的推动下适应新常态，预计将逐步復苏。

预计慢性感觉障碍产业在预测期内将是最大的

慢性感觉异常细分市场预计将成长最大份额。随着糖尿病、週边神经病变和自体自体免疫疾病等慢性疾病在全球的盛行率不断上升，越来越多的人遭受持续性和復发性感觉障碍。慢性感觉异常的特征是长期或反覆出现异常感觉，例如刺痛或麻木，需要持续有效的治疗策略。此外，这种日益普遍的现象刺激了对有针对性的持久解决方案的需求，并促进了慢性感觉麻木的蔓延。

预计零售药局领域在预测期内复合年增长率最高

零售药房业务预计将保持良好成长。随着对麻木和相关神经系统疾病的认识不断增强，人们寻求更容易获得和方便的方法来获得治疗和药物。零售药局是各种药物的重要分销点，包括缓解麻木症状的药物。零售药局可以方便地获得成药药和处方药，使广大患者可以获得感觉异常的治疗。

比例最高的地区：

在中国、印度和日本等国家，慢性病盛行率不断上升，人口迅速老化，导致与感觉障碍相关的疾病发生率上升，感觉障碍治疗市场显着成长。人们对神经系统疾病及其治疗的认识不断提高，增加了该地区对有效感觉障碍治疗的需求。此外，医疗基础设施的发展、积极的政府措施以及医疗支出的快速成长也促进了该地区的市场成长。

复合年增长率最高的地区：

欧洲地区在预测期内正在快速成长，因为该地区的法规环境支持技术创新并鼓励神经病学和神经调节领域的研发活动。医疗保健投资的迅速增加以及对以患者为中心的护理的重视，使欧洲成为感觉障碍治疗方法进展的中心。由于医疗技术的进步、医疗保健支出的增加和意识的提高，该市场不断增长。此外，製药公司和医疗保健提供者之间的区域合作正在加速研究和开发工作，并在该地区创造新的治疗选择。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球感觉异常治疗市场：依类型

  • 慢性感觉异常
  • 急性感觉异常
  • 其他类型

第六章全球感觉异常治疗市场：依治疗分类

  • 热带奶油
    • Prilocaine
    • 利多卡因
    • 其他热带乳霜
  • 抗惊厥药
  • 免疫抑制剂
    • 静脉注射丙种球蛋白
    • 强的松
    • 其他免疫抑制剂
  • 抗病毒药物
  • 其他治疗方法

第七章全球感觉异常治疗市场：依原因分类

  • 神经受压迫
  • 神经损伤
  • 代谢紊乱
  • 其他原因

第八章全球感觉异常治疗市场：按分销管道

  • 零售药房
  • 医院药房
  • 网路药房
  • 直接竞标
  • 其他分销管道

第九章全球感觉异常治疗市场：依最终用户分类

  • 诊所
  • 居家护理
  • 诊断中心
  • 其他最终用户

第十章全球感觉异常治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Abbott Laboratories
  • AstraZeneca
  • Baxter International Inc.
  • Boston Scientific Corporation
  • Cipla Ltd
  • ElectroCore LLC
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Nevro Corp
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stimwave LLC
  • Stryker Corp
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC24721

According to Stratistics MRC, the Global Paresthesia Treatment Market is accounted for $5.39 billion in 2023 and is expected to reach $7.89 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The Paresthesia Treatment Market refers to the economic domain encompassing the various products and services aimed at diagnosing, managing, and alleviating symptoms of paresthesia-a neurological condition characterized by abnormal sensations such as tingling, numbness, and burning. It provides a spectrum of therapeutic options, including pharmaceuticals, neuromodulation devices, and rehabilitation therapies, tailored to alleviate the symptoms of paresthesia and its underlying causes.

According to the World Health Organization, the number of people aged over 60 years and above was around 1 billion in 2020 and is projected to reach over 1.4 billion people by 2030.

Market Dynamics:

Driver:

Increasing incidences of chronic illnesses

As chronic conditions such as diabetes, neuropathy, and autoimmune disorders become more widespread, the incidence of paresthesia, characterized by abnormal sensations like tingling and numbness, has witnessed a proportional rise. Paresthesia often manifests as a symptom of underlying medical issues, prompting an increased demand for effective treatments and management strategies. Additionally, healthcare providers are compelled to address the growing patient pool seeking relief from paresthesia-related discomfort, fostering the expansion of the treatment market.

Restraint:

Possibility of adverse effects linked to specific treatment modalities

Certain patients may have negative reactions, discomfort, or complications from interventions like nerve stimulation or medication therapy. This may prevent these treatments from being widely used because patient and physician acceptance may be restricted due to worries about safety and tolerability. However, it is challenging because individual responses to treatments vary, so healthcare providers must carefully evaluate and customize interventions for each patient.

Opportunity:

Increasing need for neuromodulation treatments

Neuromodulation, encompassing various techniques such as spinal cord stimulation and peripheral nerve stimulation, has gained prominence as an effective approach in managing paresthesia and associated neurological disorders. With an increasing prevalence of chronic conditions like neuropathy and spinal disorders, there is a growing demand for advanced therapeutic interventions that directly target the nervous system to alleviate symptoms like tingling and numbness. Neuromodulation techniques offer a tailored and minimally invasive solution, providing patients with a viable alternative when traditional treatments prove insufficient.

Threat:

Negative consequences related to current treatment methods

The possibility of negative side effects and complications from current treatment modalities poses a serious threat to the paresthesia treatment market. Treatments for paresthesia that involve risks like infection, device malfunction, or unintentional nerve damage include spinal cord stimulation and medications. However, the market dominance of existing treatments may be threatened by developments in alternative therapies or emerging technologies. In order to lessen these risks in the ever-changing paresthesia treatment market, it will be essential to maintain the safety and effectiveness of current strategies and to consistently innovate.

COVID-19 Impact:

The paresthesia treatment market has been severely impacted by the COVID-19 pandemic. The creation and uptake of paresthesia treatments have slowed down as a result of disruptions in healthcare services, issues with the supply chain, and a shift in focus toward pandemic management. However, opportunities for online consultations and at-home treatments have been made possible by the growing emphasis on telemedicine and remote patient monitoring. It is anticipated to progressively rebound as the healthcare industry adjusts to the new normal, propelled by technological developments and the return of routine medical care.

The chronic paresthesia segment is expected to be the largest during the forecast period

The chronic paresthesia segment is expected to grow at a largest share. With a rising global incidence of chronic health conditions such as diabetes, peripheral neuropathy, and autoimmune disorders, a growing population is experiencing persistent and recurrent paresthesia. Chronic paresthesia, characterized by long-term or recurring abnormal sensations like tingling and numbness, necessitates sustained and effective treatment strategies. Moreover, this increasing prevalence has fueled a demand for targeted and enduring solutions, driving the expansion of the chronic paresthesia.

The retail pharmacy segment is expected to have the highest CAGR during the forecast period

Retail Pharmacy segment is projected to hold lucrative growth. As awareness about paresthesia and related neurological disorders increases, individuals seek accessible and convenient avenues for obtaining treatment and medications. Retail pharmacies serve as crucial distribution points for a wide array of pharmaceutical products, including those designed to alleviate symptoms of paresthesia. The ease of access to over-the-counter medications and prescription drugs at retail pharmacies enhances the availability of paresthesia treatments to a broad spectrum of patients.

Region with largest share:

Due to increasing prevalence of chronic diseases, coupled with a rapidly growing aging population in countries like China, India, and Japan, has led to a rising incidence of paresthesia-related conditions, the Asia-Pacific paresthesia treatment market has grown substantially. As awareness about neurological disorders and their management improves, there is a heightened demand for effective paresthesia treatments in the region. Additionally, the evolving healthcare infrastructure, favorable government initiatives, and a surge in healthcare spending contribute to the market's growth in the region.

Region with highest CAGR:

As the region's regulatory environment supports innovation, encouraging research and development activities in the field of neurology and neuromodulation, Europe region is growing at a rapid pace over the projected period. A surge in healthcare investments, coupled with a strong focus on patient-centric care, positions Europe as a hub for advancements in paresthesia treatment modalities. The market has grown as a result of medical technology advancements, increased healthcare spending, and growing awareness. Furthermore, research and development efforts have been fueled by regional partnerships between pharmaceutical companies and healthcare providers, which have resulted in novel treatment options in the region.

Key players in the market:

Some of the key players in Paresthesia Treatment market include Abbott Laboratories, AstraZeneca, Baxter International Inc., Boston Scientific Corporation, Cipla Ltd, ElectroCore LLC, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V, Nevro Corp, Novartis AG, Pfizer Inc., Sanofi, Stimwave LLC, Stryker Corp and Teva Pharmaceutical Industries Ltd.

Key Developments:

In December 2023, AstraZeneca Pharma India Ltd. has signed a memorandum of understanding (MoU) with Roche Diagnostics India to improve diagnostics for breast cancer patients with a key focus to streamlining HER2 diagnostics with newer advancements in the field. As per the partnership, comprehensive training initiatives for pathologists and medical oncologists will be imparted. Training modules designed for oncologists will cover advances in HER-2 testing and HER-2 low interpretations.

In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

Types Covered:

  • Chronic Paresthesia
  • Acute Paresthesia
  • Other Types

Treatments Covered:

  • Tropical Creams
  • Anticonvulsants
  • Immunosuppressant
  • Antivirals
  • Other Treatments

Causes Covered:

  • Nerve Compression
  • Nerve Damage
  • Metabolic Disorders
  • Other Causes

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
  • Direct Tenders
  • Other Distribution Channels

End Users Covered:

  • Clinics
  • Homecare
  • Diagnosis Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Paresthesia Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Chronic Paresthesia
  • 5.3 Acute Paresthesia
  • 5.4 Other Types

6 Global Paresthesia Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Tropical Creams
    • 6.2.1 Prilocaine
    • 6.2.2 Lidocaine
    • 6.2.3 Other Tropical Creams
  • 6.3 Anticonvulsants
  • 6.4 Immunosuppressant
    • 6.4.1 Intravenous Gamma Globulin
    • 6.4.2 Prednisone
    • 6.4.3 Other Immunosuppressants
  • 6.5 Antivirals
  • 6.6 Other Treatments

7 Global Paresthesia Treatment Market, By Cause

  • 7.1 Introduction
  • 7.2 Nerve Compression
  • 7.3 Nerve Damage
  • 7.4 Metabolic Disorders
  • 7.5 Other Causes

8 Global Paresthesia Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Hospital Pharmacy
  • 8.4 Online Pharmacy
  • 8.5 Direct Tenders
  • 8.6 Other Distribution Channels

9 Global Paresthesia Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Clinics
  • 9.3 Homecare
  • 9.4 Diagnosis Centers
  • 9.5 Other End Users

10 Global Paresthesia Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AstraZeneca
  • 12.3 Baxter International Inc.
  • 12.4 Boston Scientific Corporation
  • 12.5 Cipla Ltd
  • 12.6 ElectroCore LLC
  • 12.7 Eli Lilly and Company
  • 12.8 GlaxoSmithKline plc
  • 12.9 Johnson & Johnson Services, Inc.
  • 12.10 Merck & Co., Inc.
  • 12.11 Mylan N.V
  • 12.12 Nevro Corp
  • 12.12 Novartis AG
  • 12.14 Pfizer Inc.
  • 12.15 Sanofi
  • 12.16 Stimwave LLC
  • 12.17 Stryker Corp
  • 12.18 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Paresthesia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 2 Global Paresthesia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Paresthesia Treatment Market Outlook, By Chronic Paresthesia (2021-2030) ($MN)
  • Table 4 Global Paresthesia Treatment Market Outlook, By Acute Paresthesia (2021-2030) ($MN)
  • Table 5 Global Paresthesia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Paresthesia Treatment Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 7 Global Paresthesia Treatment Market Outlook, By Tropical Creams (2021-2030) ($MN)
  • Table 8 Global Paresthesia Treatment Market Outlook, By Prilocaine (2021-2030) ($MN)
  • Table 9 Global Paresthesia Treatment Market Outlook, By Lidocaine (2021-2030) ($MN)
  • Table 10 Global Paresthesia Treatment Market Outlook, By Other Tropical Creams (2021-2030) ($MN)
  • Table 11 Global Paresthesia Treatment Market Outlook, By Anticonvulsants (2021-2030) ($MN)
  • Table 12 Global Paresthesia Treatment Market Outlook, By Immunosuppressant (2021-2030) ($MN)
  • Table 13 Global Paresthesia Treatment Market Outlook, By Intravenous Gamma Globulin (2021-2030) ($MN)
  • Table 14 Global Paresthesia Treatment Market Outlook, By Prednisone (2021-2030) ($MN)
  • Table 15 Global Paresthesia Treatment Market Outlook, By Other Immunosuppressants (2021-2030) ($MN)
  • Table 16 Global Paresthesia Treatment Market Outlook, By Antivirals (2021-2030) ($MN)
  • Table 17 Global Paresthesia Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 18 Global Paresthesia Treatment Market Outlook, By Cause (2021-2030) ($MN)
  • Table 19 Global Paresthesia Treatment Market Outlook, By Nerve Compression (2021-2030) ($MN)
  • Table 20 Global Paresthesia Treatment Market Outlook, By Nerve Damage (2021-2030) ($MN)
  • Table 21 Global Paresthesia Treatment Market Outlook, By Metabolic Disorders (2021-2030) ($MN)
  • Table 22 Global Paresthesia Treatment Market Outlook, By Other Causes (2021-2030) ($MN)
  • Table 23 Global Paresthesia Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 24 Global Paresthesia Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 25 Global Paresthesia Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 26 Global Paresthesia Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 27 Global Paresthesia Treatment Market Outlook, By Direct Tenders (2021-2030) ($MN)
  • Table 28 Global Paresthesia Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 29 Global Paresthesia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Paresthesia Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 31 Global Paresthesia Treatment Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 32 Global Paresthesia Treatment Market Outlook, By Diagnosis Centers (2021-2030) ($MN)
  • Table 33 Global Paresthesia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.